Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
-
8941
Antimycin A treatment decreases respiratory internal rotenone-insensitive NADH oxidation capacity in potato leaves-4
Published 2011“…Black columns, leaves sprayed with 10 μM antimycin A. Transcript abundance is shown for 1 (A), TC54504 (B) and the 28.5 kDa subunit of complex I (C). …”
-
8942
Additional file 5 of Organization of self-advantageous niche by neural stem/progenitor cells during development via autocrine VEGF-A under hypoxia
Published 2023“…NeuN+ neurons were significantly decreased by the hypoxic condition (Mean ± SEM, n = 4, *** p = 0.00028. …”
-
8943
Global average ignition delay time of oil droplets with volume of 0.1-0.5ml.
Published 2025Subjects: -
8944
-
8945
Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do...
Published 2019“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
-
8946
Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do...
Published 2019“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
-
8947
Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do...
Published 2022“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
-
8948
Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do...
Published 2022“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
-
8949
-
8950
-
8951
-
8952
-
8953
Percentage change in total volume of salt sold by category and company, 2015–2020.
Published 2022Subjects: -
8954
-
8955
-
8956
Supplementary Material for: 3,4-Methylenedioxymethamphetamine (Ecstasy) Decreases Inflammation and Airway Reactivity in a Murine Model of Asthma
Published 2012“…We also showed that MDMA decreased expression of both Th2-like cytokines (IL-4, IL-5 and IL-10) and adhesion molecules (L-selectin). …”
-
8957
-
8958
<i>C. burnetii</i> utilizes α<sub>V</sub>β<sub>3</sub> integrin for uptake in a cholesterol-dependent manner.
Published 2013“…When +cholesterol cells were pre-incubated with vitronectin, the major ligand for a α<sub>V</sub>β<sub>3</sub> integrin, <i>C. burnetii</i> entry decreased by 66% (p = 0.001) and 71% (p<0.0001) as compared to pre-incubation with fibronectin or BSA, respectively. …”
-
8959
-
8960